Perrigo Buys Remaining Stake in Cobrek Pharma for ~$45M
Perrigo Company (Nasdaq: PRGO) today announced that it has signed a definitive merger agreement and has completed the acquisition of Cobrek Pharmaceuticals, Inc. (Cobrek), a privately-held, Chicago, Illinois-based drug development company, for approximately $45 million on a cash free and debt free basis.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.